These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
265 related articles for article (PubMed ID: 31870597)
21. Assessment of the Viala B; Zaidi FZ; Bastide M; Dumont Y; Le Moing V; Jean-Pierre H; Godreuil S Microb Drug Resist; 2019 Nov; 25(9):1325-1329. PubMed ID: 31225764 [No Abstract] [Full Text] [Related]
22. WCK 4234, a novel diazabicyclooctane potentiating carbapenems against Enterobacteriaceae, Pseudomonas and Acinetobacter with class A, C and D β-lactamases. Mushtaq S; Vickers A; Woodford N; Livermore DM J Antimicrob Chemother; 2017 Jun; 72(6):1688-1695. PubMed ID: 28333319 [TBL] [Abstract][Full Text] [Related]
23. Plasma and Intrapulmonary Concentrations of Cefepime and Zidebactam following Intravenous Administration of WCK 5222 to Healthy Adult Subjects. Rodvold KA; Gotfried MH; Chugh R; Gupta M; Patel A; Chavan R; Yeole R; Friedland HD; Bhatia A Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29784852 [TBL] [Abstract][Full Text] [Related]
27. Evaluation of Susceptibility Testing Methods for Aztreonam and Ceftazidime-Avibactam Combination Therapy on Extensively Drug-Resistant Gram-Negative Organisms. Khan A; Erickson SG; Pettaway C; Arias CA; Miller WR; Bhatti MM Antimicrob Agents Chemother; 2021 Oct; 65(11):e0084621. PubMed ID: 34424044 [TBL] [Abstract][Full Text] [Related]
28. Activity of Meropenem with a Novel Broader-Spectrum β-Lactamase Inhibitor, WCK 4234, against Gram-Negative Pathogens Endemic to New York City. Iregui A; Khan Z; Landman D; Quale J Antimicrob Agents Chemother; 2019 Dec; 64(1):. PubMed ID: 31611363 [TBL] [Abstract][Full Text] [Related]
29. In vitro activity of imipenem/relebactam, meropenem/vaborbactam, ceftazidime/avibactam, cefepime/zidebactam and other novel antibiotics against imipenem-non-susceptible Gram-negative bacilli from Taiwan. Kuo SC; Wang YC; Tan MC; Huang WC; Shiau YR; Wang HY; Lai JF; Huang IW; Lauderdale TL J Antimicrob Chemother; 2021 Jul; 76(8):2071-2078. PubMed ID: 33956969 [TBL] [Abstract][Full Text] [Related]
30. Assessment of Activity and Resistance Mechanisms to Cefepime in Combination with the Novel β-Lactamase Inhibitors Zidebactam, Taniborbactam, and Enmetazobactam against a Multicenter Collection of Carbapenemase-Producing Vázquez-Ucha JC; Lasarte-Monterrubio C; Guijarro-Sánchez P; Oviaño M; Álvarez-Fraga L; Alonso-García I; Arca-Suárez J; Bou G; Beceiro A; Antimicrob Agents Chemother; 2022 Feb; 66(2):e0167621. PubMed ID: 34807754 [TBL] [Abstract][Full Text] [Related]
31. In vitro activity of cefepime/zidebactam and cefepime/taniborbactam against aztreonam/avibactam-resistant NDM-like-producing Escherichia coli clinical isolates. Le Terrier C; Nordmann P; Sadek M; Poirel L J Antimicrob Chemother; 2023 May; 78(5):1191-1194. PubMed ID: 36921067 [TBL] [Abstract][Full Text] [Related]
32. Efficacy of human-simulated bronchopulmonary exposures of cefepime, zidebactam and the combination (WCK 5222) against MDR Pseudomonas aeruginosa in a neutropenic murine pneumonia model. Kidd JM; Abdelraouf K; Nicolau DP J Antimicrob Chemother; 2020 Jan; 75(1):149-155. PubMed ID: 31641765 [TBL] [Abstract][Full Text] [Related]
33. In vitro activity of avibactam (NXL104) in combination with β-lactams against Gram-negative bacteria, including OXA-48 β-lactamase-producing Klebsiella pneumoniae. Aktaş Z; Kayacan C; Oncul O Int J Antimicrob Agents; 2012 Jan; 39(1):86-9. PubMed ID: 22041508 [TBL] [Abstract][Full Text] [Related]
34. Comparative in vivo activity of human-simulated plasma and epithelial lining fluid exposures of WCK 5222 (cefepime/zidebactam) against KPC- and OXA-48-like-producing Klebsiella pneumoniae in the neutropenic murine pneumonia model. Lasko MJ; Abdelraouf K; Nicolau DP J Antimicrob Chemother; 2021 Aug; 76(9):2310-2316. PubMed ID: 34096601 [TBL] [Abstract][Full Text] [Related]
35. Single-Center Evaluation of the Pharmacokinetics of WCK 5222 (Cefepime-Zidebactam Combination) in Subjects with Renal Impairment. Preston RA; Mamikonyan G; DeGraff S; Chiou J; Kemper CJ; Xu A; Mastim M; Yeole R; Chavan R; Patel A; Friedland HD; Bhatia A Antimicrob Agents Chemother; 2019 Jan; 63(1):. PubMed ID: 30397067 [TBL] [Abstract][Full Text] [Related]
36. Activities of NXL104 combinations with ceftazidime and aztreonam against carbapenemase-Producing Enterobacteriaceae. Livermore DM; Mushtaq S; Warner M; Zhang J; Maharjan S; Doumith M; Woodford N Antimicrob Agents Chemother; 2011 Jan; 55(1):390-4. PubMed ID: 21041502 [TBL] [Abstract][Full Text] [Related]
38. In vivo efficacy of WCK 6777 (ertapenem/zidebactam) against carbapenemase-producing Klebsiella pneumoniae in the neutropenic murine pneumonia model. Gethers M; Chen I; Abdelraouf K; Nicolau DP J Antimicrob Chemother; 2022 Jun; 77(7):1931-1937. PubMed ID: 35411395 [TBL] [Abstract][Full Text] [Related]
39. Effective inhibition of PBPs by cefepime and zidebactam in the presence of VIM-1 drives potent bactericidal activity against MBL-expressing Pseudomonas aeruginosa. Moya B; Bhagwat S; Cabot G; Bou G; Patel M; Oliver A J Antimicrob Chemother; 2020 Jun; 75(6):1474-1478. PubMed ID: 32083659 [TBL] [Abstract][Full Text] [Related]